Hypofractionation with Simultaneous Integrated Boost for Early Breast Cancer: Results of the German Multicenter Phase II Trial (ARO-2010-01)

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2014 Apr 17

PMID 24737540

Citations 33

Authors

Kathrin Dellas

Reinhard Vonthein

Jorg Zimmer

Stefan Dinges

Alexander D Boicev

Peter Andreas

Dorothea Fischer

Cornelia Winkler

Andreas Ziegler

Jurgen Dunst

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the feasibility of hypofractionation with SIB in all settings in Germany to prepare a multicenter treatment comparison.

Methods: Eligible patients had histopathologically confirmed breast cancer operated by BCS. Patients received WBI 40.0 Gy in 16 fractions of 2.5 Gy. A SIB with 0.5 Gy per fraction was administered to the tumor bed, thereby giving 48.0 Gy in 16 fractions to the boost-PTV sparing heart, LAD, lung, contralateral breast. The primary study objective was feasibility, administration of specified dose in 16 fractions within 22-29 days with adherence to certain dose constraints (heart; LAD; contralateral breast); secondary endpoints were toxicity, QoL.

Results: 151 patients were recruited from 7 institutions between 07/11-10/12. 10 patients met exclusion criteria prior to irradiation. All but two patients (99%) received the prescribed dose in the PTVs. Adherence to dose constraints and time limits was achieved in 89% (95% CI 82% to 93%). 11 AE were reported in 10 patients; five related to concurrent endocrine therapy. Two of the AEs were related to radiotherapy: grade 3 hot flushes in two cases. QoL remained unchanged.

Conclusion: Hypofractionation with a SIB is feasible and was well tolerated in this study.

Citing Articles

Ultra-hypofractionated 5-fraction radiation therapy for early breast cancer into whole breast and regional nodes: experience in a tertiary hospital.

Tejada Ortigosa E, Ollinger Casin I, Gaztelu Blanco I, Muniz Romero G, de Haro Piedra R Clin Transl Oncol. 2024; .

PMID: 39680268 DOI: 10.1007/s12094-024-03786-w.

Comparison of helical and TomoDirect techniques with simultaneous integrated boost in early breast cancer patients.

Onal C, Bozca R, Oymak E, Guler O Rep Pract Oncol Radiother. 2023; 28(4):541-550.

PMID: 37795226 PMC: 10547420. DOI: 10.5603/RPOR.a2023.0058.

Journey to hypofractionation in radiotherapy for breast cancer: critical reviews for recent updates.

Kim N, Kim Y Radiat Oncol J. 2023; 40(4):216-224.

PMID: 36606299 PMC: 9830038. DOI: 10.3857/roj.2022.00577.

Knowledge-based automatic plan optimization for left-sided whole breast tomotherapy.

Esposito P, Castriconi R, Mangili P, Broggi S, Fodor A, Pasetti M Phys Imaging Radiat Oncol. 2022; 23:54-59.

PMID: 35814259 PMC: 9256826. DOI: 10.1016/j.phro.2022.06.009.

Long-term oncological outcomes of hypofractionated versus conventional fractionated whole breast irradiation with simultaneous integrated boost in early-stage breast cancer.

Lertbutsayanukul C, Pitak M, Nantavithya C Radiat Oncol J. 2022; 40(2):141-150.

PMID: 35796117 PMC: 9262705. DOI: 10.3857/roj.2021.00927.

References

Sedlmayer F, Sautter-Bihl M, Budach W, Dunst J, Feyer P, Fietkau R . Is the simultaneously integrated boost (SIB) technique for early breast cancer ready to be adopted for routine adjuvant radiotherapy? Statement of the German and the Austrian Societies of Radiooncology (DEGRO/ÖGRO). Strahlenther Onkol. 2013; 189(3):193-6. DOI: 10.1007/s00066-012-0300-3. View

Livi L, Borghesi S, Saieva C, Fambrini M, Iannalfi A, Greto D . Benefit of radiation boost after whole-breast radiotherapy. Int J Radiat Oncol Biol Phys. 2009; 75(4):1029-34. DOI: 10.1016/j.ijrobp.2008.12.038. View

Bartelink H, Horiot J, Poortmans P, Struikmans H, Van den Bogaert W, Fourquet A . Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007; 25(22):3259-65. DOI: 10.1200/JCO.2007.11.4991. View

Owen J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J . Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006; 7(6):467-71. DOI: 10.1016/S1470-2045(06)70699-4. View

Azria D, Auvray H, Barillot I, Baumann P, Benyoucef A, Bons-Rosset F . [Ductal carcinoma in situ: role of the boost]. Cancer Radiother. 2008; 12(6-7):571-6. DOI: 10.1016/j.canrad.2008.07.005. View

Chadha M, Vongtama D, Friedmann P, Parris C, Boolbol S, Woode R . Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer. Clin Breast Cancer. 2011; 12(1):57-62. DOI: 10.1016/j.clbc.2011.09.002. View

Agrawal R, Aird E, Barrett J, Barrett-Lee P, Bentzen S, Bliss J . The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008; 371(9618):1098-107. PMC: 2277488. DOI: 10.1016/S0140-6736(08)60348-7. View

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V . Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366(9503):2087-106. DOI: 10.1016/S0140-6736(05)67887-7. View

Van Parijs H, Miedema G, Vinh-Hung V, Verbanck S, Adriaenssens N, Kerkhove D . Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial. Radiat Oncol. 2012; 7:80. PMC: 3432009. DOI: 10.1186/1748-717X-7-80. View

10.

Darby S, Ewertz M, McGale P, Bennet A, Blom-Goldman U, Bronnum D . Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013; 368(11):987-98. DOI: 10.1056/NEJMoa1209825. View

11.

Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M . Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804):1707-16. PMC: 3254252. DOI: 10.1016/S0140-6736(11)61629-2. View

12.

Sedlmayer F, Sautter-Bihl M, Budach W, Dunst J, Fastner G, Feyer P . DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer. Strahlenther Onkol. 2013; 189(10):825-33. PMC: 3825416. DOI: 10.1007/s00066-013-0437-8. View

13.

Bentzen S, Agrawal R, Aird E, Barrett J, Barrett-Lee P, Bliss J . The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008; 9(4):331-41. PMC: 2323709. DOI: 10.1016/S1470-2045(08)70077-9. View

14.

Whelan T, Pignol J, Levine M, Julian J, MacKenzie R, Parpia S . Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010; 362(6):513-20. DOI: 10.1056/NEJMoa0906260. View

15.

Whelan T, Julian J, Wright J, Jadad A, LEVINE M . Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000; 18(6):1220-9. DOI: 10.1200/JCO.2000.18.6.1220. View

16.

Scorsetti M, Alongi F, Fogliata A, Pentimalli S, Navarria P, Lobefalo F . Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments. Radiat Oncol. 2012; 7:145. PMC: 3488023. DOI: 10.1186/1748-717X-7-145. View